Bio Standard Announces 3rd Quarter Revenue Increase for Palm Beach Rejuvenation Centres.

Business/Health Editors

WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Oct. 16, 2002

Bio Standard Corporation (OTCBB:BSTN) announced that revenues of Palm Beach Rejuvenation Centres (PBRC) for the nine-month period ended September 30, 2002 increased to $3,295,482 from $751,630 for the comparable period of 2001 or an increase of 338%.

Revenues for the three-month period ended September 30, 2002 were $1,402,594 compared to $433,841 for the same period of 2001 or an increase of 223%. BSTN owns 21% and has the right to acquire an additional 59% of PBRC, a fast growing biotech company engaged in the business of marketing Human Growth Hormone and Testosterone Therapy.

The matters discussed in this release contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, that involve risks and uncertainties. All statements other than statements of historical information provided herein may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects" and similar expressions are intended to identify forward-looking statements. Factors that could cause actual results to differ materially from those that we may anticipate include without limitation, continued acceptance of the PBRC's products and services, increased levels of competition, new products and scientific changes, the dependence upon financing, third party suppliers, the rules of regulatory authorities and risks associated with any potential acquisitions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis, judgment, belief or expectation only as of the date hereof.